Solid lipid nanoparticles of irbesartan: preparation, characterization, optimization and pharmacokinetic studies

Solid lipid nanoparticles of irbesartan: preparation, characterization, optimization and pharmacokinetic studies

ABSTRACT Irbesartan is an antihypertensive with limited bioavailability and solid lipid nanoparticles (SLN) is one of the approaches to improve bioavailability. Solid lipid nanoparticles were prepared using glyceryl monostearate by solvent emulsification method followed by probe sonication. Irbesart...

Full description

Bibliographic Details
Main Authors:	Deepthi Soma, Zenab Attari, Meka Sreenivasa Reddy, Atmakuri Damodaram, Kunnatur Balasundara Gupta Koteshwara
Format:	Article
Language:	English
Published:	Universidade de São Paulo 2017-04-01
Series:	Brazilian Journal of Pharmaceutical Sciences
Subjects:	Irbesartan/pharmacokinetics Irbesartan/preparation Irbesartan/bioavailability Glyceryl monostearate Solid lipid nanoparticles/characterization
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502017000100602&lng=en&tlng=en

Similar Items

Irbesartan; An Antihypertensive Drug Reduces LDL-Cholesterol in Diet Induced Hyperlipidemic Rabbits
by: Sabeen Shakir , Akbar Waheed , Noureen Hafeez
Published: (2016-09-01)

Comparative bioavailability of a newly developed Irbesartan 300 mg containing preparation
by: Petrov Andrey D., et al.
Published: (2018-01-01)

Pharmacokinetic interaction between irbesartan and Orthosiphon stamineus extract in rat plasma
by: Nur Meilis, et al.
Published: (2016-02-01)

Study of influence of Catha edulis (Khat) chewing on oral pharmacokinetics of irbesartan in rats using a newly developed HPLC-UV method
by: Hassan A. Alhazmi, et al.
Published: (2022-03-01)

Irbesartan attenuates renal injury with diabetic nephropathy rats
by: ZHANG Ya, HUANG Wen-hui, HOU Zhi-min, LIU Ju-xiang, LIU Jing
Published: (2020-04-01)

Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients withtype 2 diabetes mellitus and mild hypertension:a sequential, randomized, double-blind clinical trial
by: - Giuseppe Derosa, et al.
Published: (2009-03-01)

Observational study on patients’ compliance with Irbesartan in essential hypertension “I Comply”
by: K. Leon, et al.
Published: (2014-03-01)

Changes of Necroptosis in Irbesartan Medicated Cardioprotection in Diabetic Rats
by: Xu Q, et al.
Published: (2021-09-01)

IRBESARTAN IN THE CLINICAL PRACTICE
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

HPLC method with monolithic column for simultaneous determination of irbesartan and hydrochlorothiazide in tablets
by: Alanazi Amer M., et al.
Published: (2014-06-01)

Oral Formulation Based on Irbesartan Nanocrystals Improve Drug Solubility, Absorbability, and Efficacy
by: Noriaki Nagai, et al.
Published: (2022-02-01)

Renoprotective effect of irbesartan in a rat model of gentamicin-induced nephrotoxicity: Role of oxidative stress
by: Hayder M. Al-Kuraishy, et al.
Published: (2019-07-01)

Clinical case: Effectiveness of combined therapyOrlistat and Irbesartan at the Metabolic syndrome patient with Arterial hypertension
by: K P Ivanov, et al.
Published: (2009-03-01)

Nanocrystalline Suspensions of Irbesartan Enhance Oral Bioavailability by Improving Drug Solubility and Leading Endocytosis Uptake into the Intestine
by: Saori Deguchi, et al.
Published: (2021-09-01)

Effect of Irbesartan on Chemerin in the Renal Tissues of Diabetic Rats
by: Qiu-Xia Yu, et al.
Published: (2015-09-01)

Formulation and development of a self-nanoemulsifying drug delivery system of irbesartan
by: Jaydeep Patel, et al.
Published: (2011-01-01)

Cyclodextrin Complexed Lipid Nanoparticles of Irbesartan for Oral Applications: Design, Development, and In Vitro Characterization
by: Narendar Dudhipala, et al.
Published: (2021-12-01)

Effect of solubilization technique on dissolution
by: Sujoy Das, et al.
Published: (2014-02-01)

Eficacia y seguridad en la vida real de amlodipino/irbesartán en combinación fija en el tratamiento de la hipertensión en América Latina: estudio PARCERIA
by: Álvaro J. Ruiz, et al.
Published: (2023-01-01)

Comparison of efficacy and safety between two different irbesartan, generic vs branded, in the treatment of Korean patients with mild-to-moderate hypertension: an 8-week, multicenter, randomized, open-label, Phase IV clinical study
by: Han SH, et al.
Published: (2018-12-01)

Efficacy of a fixed dose combination of irbesartan and atorvastatin (Rovelito®) in Korean adults with hypertension and hypercholesterolemia
by: Ihm SH, et al.
Published: (2019-02-01)

Irbesartan attenuates gentamicin-induced nephrotoxicity in rats through modulation of oxidative stress and endogenous antioxidant capacity
by: Hayder M Al-kuraishy, et al.
Published: (2020-01-01)

Studies on jackfruit seed starch as a novel natural superdisintegrant for the design and evaluation of irbesartan fast dissolving tablets
by: Vidyadhara Suryadevara, et al.
Published: (2017-09-01)

A Fast and Validated Reversed-Phase HPLC Method for Simultaneous Determination of Simvastatin, Atorvastatin, Telmisartan and Irbesartan in Bulk Drugs and Tablet Formulations
by: Hassan A. Alhazmi, et al.
Published: (2017-12-01)

Combined treatment of irbesartan and diltiazem ameliorates endothelium dependent vasodilatation in hypertensives
by: Tingting Zhou, et al.
Published: (2017-10-01)

Irbesartan Ameliorates Lipid Deposition by Enhancing Autophagy via PKC/AMPK/ULK1 Axis in Free Fatty Acid Induced Hepatocytes
by: Juan He, et al.
Published: (2019-05-01)

Efficiency assessment for antihypertensive, hemodynamic, renal effects of adenosine-converting enzyme (ACE) inhibitors and irbesartan and impact on endothelial disfunction in patients with stage II hypertension
by: M. V. Pereviazkina
Published: (2014-08-01)

Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patierns with type 2 diabetes, hypertension, and renal disease in Switzerland
by: AJ Palmer, et al.
Published: (2006-05-01)

Effects of irbesartan on phenotypic alterations in monocytes and the inflammatory status of hypertensive patients with left ventricular hypertrophy
by: Jingsi Zhang, et al.
Published: (2021-04-01)

Dynamics of testosterone and prolactin levels, blood pressure and parameters of cardiovascular remodeling in hypertensive men with androgen deficiency in the course of treatment
by: V. A. Vizir, et al.
Published: (2019-07-01)

Spectroscopic and in silico approach to probe the binding interactions of irbesartan and human serum albumin
by: Asim Najmi, et al.
Published: (2022-04-01)

Management of hypertension with fixed-dose combination of irbesartan and amlodipine: A real-life observation
by: Elie Chammas
Published: (2022-01-01)

Late-Onset Rash from Irbesartan: An Immunological Reaction
by: Bárbara Kong Cardoso, et al.
Published: (2019-06-01)

Chronomodulated drug delivery system of Irbesartan: Formulation and development using Desing of Experiment (DoE)
by: Komal Parmar, et al.
Published: (2018-06-01)

Effect of administration of low‐dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non‐dipper patients with grade 1 and 2 hypertension
by: Peiling Yan, et al.
Published: (2023-02-01)

Preparation and Evaluation of Oroslippery Tablets Contain Irbesartan and Hydrochlorothiazide Combination for Dysphagia Patients
by: Yasir Q. almajidi, et al.
Published: (2022-12-01)

The combination therapy in arterial hypertension: opportunities of the fixed combination of irbesartan andhydrochlorothiazide(Koaprovel’)
by: O D Ostroumova, et al.
Published: (2014-09-01)

Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis
by: Tianxing Zhou, et al.
Published: (2023-05-01)

Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study
by: E. Titmuss, et al.
Published: (2023-03-01)

About INCLUSIVE study
by: G. Pinna
Published: (2013-05-01)